Search results
Showing 1606 to 1620 of 1809 results for nice guidelines
This evidence summary has been updated and replaced by NICE guideline NG17.
Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)
This evidence summary has been updated and replaced by NICE guideline NG71.
Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)
This evidence summary has been updated and replaced by NICE guideline NG201.
SeQuent Please balloon catheter for in-stent coronary restenosis (MTG1)
This medical technologies guidance has been replaced by the recommendations in the NICE guideline on acute coronary syndromes.
This guidance has been withdrawn as the use of this procedure is now covered in the NICE guideline on heavy menstrual bleeding: assessment and management. NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.
Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)
This evidence summary has been updated and replaced by the NICE guideline CG178 (published February 2014).
This evidence summary has been updated and replaced by NICE guideline CG113 and subsequent surveillance reviews.
This medical technologies guidance has been replaced by the recommendation on cardiac output monitoring in the NICE guideline on perioperative care in adults.
HealthVCF for detecting vertebral compression fractures on CT scans (MIB267)
NICE has developed a medtech innovation briefing (MIB) on HealthVCF for detecting vertebral compression fractures on CT scans .
Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (TA93)
This guidance has been updated and replaced by NICE guideline NG151. The recommendations on raltitrexed have been withdrawn because its use is established clinical practice.
This evidence summary has been withdrawn because licensed products are now available and the off-label indication has been replaced by NICE guideline NG71.
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)
Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.
Meningitis (bacterial) and meningococcal septicaemia in children and young people (QS19)
March 2024: We have temporarily withdrawn this quality standard due to the update to the NICE guideline on meningitis, which underpins the quality statements.
See the quality standard in development page. for progress on this update.
AcQMap for mapping the heart atria to target ablation treatment for arrhythmias (MIB246)
NICE has developed a medtech innovation briefing (MIB) on AcQMap for mapping the heart atria to target ablation treatment for arrhythmias .